Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2009, Article ID 906167, 7 pages
Review Article

PPAR and Liver Injury in HIV-Infected Patients

1INSERM, UMR_S U893, CDR Saint-Antoine, 75012 Paris, France
2UPMC University Paris 06, UMR_S 893, CDR Saint-Antoine, 75012 Paris, France
3APHP Tenon and Saint-Antoine Hospitals, 75012 Paris, France
4Service d'Hépatologie, Hôpital Saint-Antoine, AP-HP, 184 rue du Faubourg Saint-Antoine, 75571 Paris Cedex 12, France

Received 10 October 2008; Accepted 31 January 2009

Academic Editor: Michal Toborek

Copyright © 2009 Maud Lemoine et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Due to the introduction of active HIV antiretroviral treatment, AIDS-related morbidity and mortality have markedly decreased and liver diseases are now a major cause of morbidity and mortality in HIV-infected patients. Chronic liver injury encompasses a wide spectrum of diseases due to HCV and HBV coinfection, drug-related toxicity, and NASH. HIV-infected patients who are receiving treatment present with a high prevalence of metabolic complications and lipodystrophy. Those patients are at high risk of nonalcoholic fatty liver disease, the liver feature of the metabolic syndrome. This review will focus on (1) the liver injuries in HIV-infected patients; (2) both the current experimental and human data regarding PPAR and liver diseases; (3) the interactions between HIV and PPAR; (4) the potential use of PPAR agonists for the management of HIV-related liver diseases.